Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date28 Nov 2024 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot ApplicableIIT A multicenter, randomized, blind subjects and evaluators, parallel, and positive control clinical study designed to evaluate the efficacy and safety for correction of moderate to severe nasolabial groove by comparing linked hyaluronic acid dermal filler with lidocaine and Restylane II for injection.
100 Clinical Results associated with BNC KOREA, Inc.
0 Patents (Medical) associated with BNC KOREA, Inc.
100 Deals associated with BNC KOREA, Inc.
100 Translational Medicine associated with BNC KOREA, Inc.